Heat shock proteins gp96 as immunogens in cancer patients.
Heat shock proteins have been the focus of many experimental studies during the last few years in order to understand their biology and their imunologic features. We conducted pre-clinical experiments showing that gp96 purified from human melanoma lines can represent melanoma antigens and stimulate T cells known to recognize such antigens. Clinical studies of vaccination were then initiated by our group by using heat-shock protein gp96 purified from autologous tumor tissues in patients with melanoma and colorectal carcinoma. The results of these trials in metastatic melanoma patients with measurable disease showed that a melanoma-specific T cell response can be generated or increased in approximately 50% of vaccinated patients. Moreover, signs of clinical responses were obtained consisting of two complete responses and three long-lasting stabilizations. Similar results were obtained in patients with liver metastases of colorectal cancer made disease-free by surgery. In both studies a clear association was found between T cell immune response induced by the vaccine and clinical response both in the trial of melanoma (tumor response) and in that of colorectal cancer patients (disease-free and overall survival at 5 years).
Parmiani
Giorgio
G
Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy. Giorgio.parmiani@istitutotumori.mi.it
De Filippo
Annamaria
A
Pilla
Lorenzo
L
Castelli
Chiara
C
Rivoltini
Licia
L
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms; D006360:Heat-Shock Proteins / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; C484813:vitespin